ASV Titration: How Pressure Settings and Algorithms Work

ASV titration is the process of dialing in the pressure settings on an adaptive servo-ventilation device so it can stabilize breathing in someone with central sleep apnea. Unlike a standard CPAP machine that delivers one fixed pressure, an ASV device adjusts its support breath by breath, responding in real time to changes in airflow. But the device still needs a framework of baseline parameters to work within, and getting those parameters right is what titration is all about. The process involves setting an expiratory pressure floor, defining the range of inspiratory pressure support the machine can deliver, and configuring a backup breathing rate. Whether this happens during an overnight sleep study in a lab or through the device’s own auto-adjusting algorithms depends on the clinical situation and the device being used.

How the ASV Algorithm Works

At its core, an ASV device continuously measures either your airflow or your minute ventilation (the total volume of air you move in a minute) and uses that measurement to calculate a target. When your breathing drops below that target, the machine increases the pressure it delivers on your inhale. When your breathing overshoots, it dials the support back down. This creates an “anticyclic” pattern of pressure delivery: the machine pushes harder when you breathe less and eases off when you breathe more, smoothing out the crescendo-decrescendo breathing pattern that defines Cheyne-Stokes respiration and other forms of central sleep apnea.¹ If you stop breathing entirely (a central apnea), the device detects the pause and can kick in a backup respiratory rate, delivering timed breaths to keep you ventilated until your own drive to breathe returns.

This is a fundamentally different approach from CPAP, which just holds the airway open with a single continuous pressure. CPAP works well for obstructive apnea, where the throat collapses, but it does not provide the kind of dynamic ventilatory support needed when the brain itself is intermittently failing to signal the muscles to breathe. ASV was designed specifically for that problem.

What Gets Adjusted During Titration

ASV titration involves three main groups of settings, each serving a distinct purpose.

Expiratory pressure (EPAP): This is the baseline pressure the device holds during exhalation, analogous to the single pressure on a CPAP machine. Its job is to keep the upper airway open and prevent obstructive events. It can be set as a fixed value or allowed to auto-adjust within a range. Some devices feature auto-EPAP algorithms that raise or lower this floor based on detected airway obstruction.
Pressure support range (minimum and maximum): Pressure support is the extra pressure delivered during inhalation on top of the EPAP. The titration sets a minimum (the least the device will add, even during stable breathing) and a maximum (a ceiling it cannot exceed, even during prolonged apneas). The device adjusts dynamically within this window.
Backup respiratory rate: If your breathing pauses long enough, the device delivers machine-initiated breaths at a set rate. Some devices allow a fixed backup rate while others use an adaptive rate pegged to your own recent breathing frequency.

The interplay between these settings matters. Setting the minimum pressure support too low might not prevent apneas from recurring, while setting the maximum too high can cause over-ventilation, which, as discussed below, has its own risks. Real-world data show that patients prescribed a minimum pressure support of at least 3 cm of water pressure were more likely to still be using their device after a year.² But pushing inspiratory pressures higher also increased residual breathing events and mask leak, creating a balancing act during titration.

In-Lab Titration vs Auto-Titrating Modes

Traditional ASV titration happens during an attended polysomnography (PSG) session in a sleep lab. A technician monitors your brain waves, airflow, oxygen levels, and chest-wall movement in real time, manually adjusting the device settings as events occur overnight. This gives the clinical team a chance to see how you respond to different pressure levels, identify any residual obstructive events that need more EPAP, and make sure the backup rate and pressure support window are appropriate.

The alternative is auto-titration, where the device itself adjusts settings based on its built-in algorithms. Some devices can auto-adjust EPAP, and all modern ASV devices dynamically adjust pressure support within the clinician-set range. In a study of chronic pain patients with central sleep apnea, researchers found clinically meaningful reductions in breathing events after just a single night on ASV, with further improvement when patients used the device at home over three months.³ This suggests that auto-titrating modes can perform well outside the lab, though the initial parameters still need to be chosen thoughtfully.

A fully automatic ASV algorithm tested in a separate study brought the median breathing disturbance index down from 11 events per hour at diagnosis to 4 events per hour during the initial sleep study, with daytime sleepiness scores dropping from about 13 to about 8 over three months.⁴ Average nightly use in that study was a little over four hours, which is consistent with the broader adherence picture for positive airway pressure therapy.

One key distinction between devices is whether the EPAP component auto-adjusts or stays fixed. In a real-world study looking at how clinicians configured ASV across different patient populations, auto-EPAP was used more often in patients without heart disease, while those with heart conditions tended to receive fixed EPAP settings.⁵ That choice turned out to matter for outcomes, a point that became much clearer after a landmark heart failure trial.

Conditions That Lead to ASV Titration

ASV is used across a range of conditions that share one feature: the brain’s breathing command signal becomes unstable during sleep. A large French cohort study documented the breakdown of ASV prescriptions in clinical practice: about 38% were for central sleep apnea related to heart or neurological disease, 36% for treatment-emergent central apnea (central apneas that appear after someone starts CPAP for obstructive apnea), 14% for idiopathic central apnea with no identifiable cause, and 11% for drug-induced central apnea, most often related to opioids.⁶

A joint statement from the European Respiratory Society and European Sleep Research Society confirmed that ASV clearly improves breathing disturbances and quality of life across all of these categories.⁷ But “improves breathing events on the sleep study” and “safe for every patient” are different questions, and the distinction has shaped how clinicians approach ASV titration in specific populations.

The Heart Failure Safety Question

The most consequential finding in the history of ASV came from the SERVE-HF trial, a large randomized study of patients who had heart failure with reduced pumping function (ejection fraction of 45% or below) and predominantly central sleep apnea. The trial found that patients randomized to ASV had higher rates of both overall death and cardiovascular death compared to those receiving standard medical care alone. The risk of death from any cause was roughly 28% higher, and cardiovascular death was about 34% higher in the ASV group.⁸

Those results were a shock to the field and immediately changed practice. Device manufacturers and sleep medicine societies issued warnings against using ASV in patients with heart failure and reduced ejection fraction. This means that before ASV titration even begins, clinicians now routinely screen for heart failure and check cardiac function. If your heart’s pumping ability is significantly reduced, ASV is generally off the table.

But subsequent research has raised the possibility that the harm seen in SERVE-HF was not inherent to all ASV devices or all settings. A single-center study that followed heart failure patients on ASV did not find the expected increase in mortality. The investigators noted that patients using ASV devices with auto-adjusting EPAP appeared to fare better than those on fixed-EPAP devices. They suggested that the SERVE-HF results may have been partly driven by the specific device and settings used in that trial, particularly the risk of over-ventilation from fixed expiratory pressures that were too high for a failing heart.⁹ This remains an active area of investigation, and the current clinical consensus still advises against ASV in this population until larger trials can clarify whether modified algorithms or lower pressure settings change the risk picture.

Heart Failure with Preserved Ejection Fraction

The SERVE-HF warning applies specifically to patients with reduced ejection fraction. A different picture emerges in heart failure patients whose pumping function is preserved (HFpEF). In a study of HFpEF patients with sleep-disordered breathing, ASV improved symptoms, cardiac relaxation function, and markers of arterial stiffness. The event-free survival rate was significantly better in the ASV-treated group compared to controls.¹⁰ A more recent study found that heart failure hospitalizations dropped dramatically in the year after ASV was started in HFpEF patients, with certain subgroups (women, patients with lower body mass, and those with significant valve regurgitation) showing the most benefit.¹¹

This distinction is critical for titration decisions. The screening question is not simply “does this patient have heart failure?” but “what type of heart failure, and what is the ejection fraction?” The answer determines whether ASV titration proceeds at all.

Why Carbon Dioxide Levels Shape Titration

Central sleep apnea is fundamentally a problem of ventilatory control, and carbon dioxide (CO2) is the key signal the brain uses to decide when to breathe. During sleep, if CO2 drops below a threshold called the apneic threshold, the brain simply stops sending the signal to inhale. In people with central apnea, the margin between their normal sleeping CO2 level and that threshold is dangerously narrow, so even small dips in CO2 can trigger a complete breathing pause.

ASV titration has to account for this. If the device over-ventilates a patient during the periods when they are breathing, it can blow off too much CO2, actually pushing them below the apneic threshold and perpetuating the very apneas the device is supposed to treat. A case report demonstrated this vividly: only ASV mode was able to keep the patient’s CO2 levels above the apneic threshold (around 40 mmHg) while eliminating central apneas, whereas other ventilation modes failed to maintain that balance.¹²

Research in heart failure patients with Cheyne-Stokes respiration showed that ASV affected CO2 levels differently depending on whether the patient was awake or asleep. While awake, CO2 tended to dip slightly (which makes sense, as the device adds ventilatory support to someone who is already breathing). During sleep, CO2 rose modestly, settling into a range that kept it above the apneic threshold.¹³ Separately, a study across multiple types of central sleep apnea found that ASV reduced chronic over-breathing as measured by blood gases, suggesting the device helped stabilize the overall ventilatory set point.¹⁴

The practical implication is that the maximum pressure support during titration should not be set so aggressively that the device over-ventilates during the breathing phases. This is one reason experienced sleep labs may use transcutaneous CO2 monitoring during in-lab ASV titration, especially in patients with narrow CO2 margins. ASV is generally not recommended for patients who already have chronically elevated CO2 levels (hypercapnia), because the algorithm assumes a patient who tends to over-breathe rather than under-breathe, and its response pattern can worsen hypoventilation in those individuals.

Treatment-Emergent Central Sleep Apnea

One of the more frustrating situations for patients is developing central apneas after starting CPAP for what was originally obstructive sleep apnea. This phenomenon, called treatment-emergent central sleep apnea, occurs in a significant minority of CPAP users. The obstructive events clear up, but central events emerge, sometimes severe enough to undermine the therapy entirely.

ASV has emerged as the treatment of choice for this population. A randomized trial comparing ASV to CPAP in patients with treatment-emergent central apnea found that about 90% of the ASV group achieved good control of their breathing events (fewer than 10 events per hour), compared to about 65% in the CPAP group.¹⁵ Titration for these patients often starts from whatever CPAP pressure was working for their obstructive events, using that as a baseline for the EPAP setting and then layering on the adaptive pressure support to address the central component.

ASV Titration for Opioid-Related Central Apnea

Chronic opioid use commonly disrupts breathing control during sleep, producing a pattern of central apneas, sometimes mixed with obstructive events and an irregular “ataxic” breathing rhythm that is particularly difficult to treat. Titrating ASV in opioid patients has its own considerations because the breathing pattern can be chaotic rather than the regular waxing-and-waning pattern seen in Cheyne-Stokes respiration.

In a retrospective study of patients on chronic opioids, ASV titration brought the central apnea index down to zero per hour, improved the lowest oxygen saturation from 83% to 90%, and cut the arousal index roughly in half.¹⁶ Another study comparing ASV success rates between opioid users and heart failure patients found no significant difference: about 60% of opioid patients and 70% of heart failure patients achieved good control.¹⁷ The success rates are lower than in treatment-emergent central apnea, reflecting the more disordered breathing pattern opioids produce, but ASV still outperformed standard CPAP for these patients.

One practical note: opioid patients frequently need higher EPAP settings to address the obstructive component of their mixed apnea, and the backup respiratory rate becomes especially important because opioids can suppress the breathing drive for longer stretches than are typical in other forms of central apnea.

Central Sleep Apnea After Stroke

Stroke can damage the brainstem areas that regulate breathing, producing persistent central sleep apnea that often goes undiagnosed during the acute recovery phase. In a study of post-stroke patients with ongoing central apnea, ASV reduced the average apnea-hypopnea index from about 47 events per hour down to roughly 9, with patients averaging over five hours of nightly use at three months and maintaining those results at six months.¹⁸ A larger randomized trial (eSATIS) has been designed to test whether starting ASV early after stroke can affect the size of brain lesions and neurological recovery, though safety protocols call for stopping treatment if patients develop chest pain, severe headache, increased breathlessness, or signs of heart failure.¹⁹

Adherence and What Predicts Long-Term Use

The best-titrated ASV settings are worthless if the patient doesn’t wear the device. Adherence data paint a mixed picture. An older trial comparing ASV to CPAP in heart failure patients with Cheyne-Stokes breathing found that at six months, quality-of-life improvements were greater with ASV and only ASV produced a significant improvement in cardiac pumping function.²⁰ Patients who feel meaningfully better tend to keep using the device.

Large-scale device data offer more granular insight. In a big-data analysis of real-world ASV users, average nightly use exceeded six hours per day across most pressure settings, which is higher than the typical four-to-five-hour average seen with standard CPAP. Patients whose 95th-percentile inspiratory pressure was higher and those prescribed a minimum pressure support of at least 3 cm of water pressure were the most likely to still be on therapy at one year.²¹ The interpretation is not entirely straightforward, since patients with more severe disease may both need higher pressures and be more motivated to use the device, but the finding does suggest that under-prescribing pressure support during titration could hurt adherence.

Alternatives When ASV Is Contraindicated or Not Tolerated

For patients who cannot use ASV, whether because of reduced-ejection-fraction heart failure, intolerance of the mask, or other reasons, several alternatives exist. Supplemental oxygen during sleep can reduce the severity of central apneas by dampening the ventilatory response to CO2 swings and may be better tolerated in patients who struggle with mask interfaces.²²

Acetazolamide, a mild diuretic that works on the kidneys to slightly acidify the blood, is sometimes used off-label for central sleep apnea. By shifting the body’s CO2 set point, it can widen the gap between normal breathing CO2 levels and the apneic threshold, making apneas less likely to occur.²³ For heart failure patients specifically, optimizing cardiac medications remains the foundation: sometimes treating the heart failure itself resolves or improves the central apnea enough that no device is needed.²⁴

Phrenic nerve stimulation is a newer alternative that works by electrically stimulating the nerve controlling the diaphragm, essentially taking over the breathing signal that the brain is failing to send. It avoids the mask interface entirely and has shown promise in patients who are not candidates for ASV, though it requires a surgical implant and long-term data are still accumulating.

Pediatric Considerations

ASV is overwhelmingly an adult therapy. A scoping review of newer noninvasive ventilation modes in children identified only a single study involving ASV in a pediatric population, compared to a dozen studies on other advanced ventilation modes.²⁵ Central sleep apnea in children has different causes and different physiology than in adults, and the ASV algorithms currently available were designed around adult breathing patterns. For clinicians who encounter a child with refractory central apnea, the evidence base for ASV titration is essentially nonexistent, and other ventilation strategies with more pediatric data are preferred.